Acumen Pharmaceuticals, Inc. (ABOS) Insider Trading Activity
NASDAQ$1.07
Market Cap
$64.81M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
395 of 877
Rank in Industry
226 of 506
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
ABOS Insider Trading Activity
ABOS Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $258,985 | 11 | 100 |
Related Transactions
| Barton Russell | Chief Operating Officer | 0 | $0 | 2 | $18,917 | $-18,917 |
| Siemers Eric | Chief Medical Officer | 0 | $0 | 2 | $25,165 | $-25,165 |
| Meisner Derek M | Chief Legal Officer & Corp Sec | 0 | $0 | 2 | $25,940 | $-25,940 |
| Zuga Matt | CFO & Chief Business Officer | 0 | $0 | 3 | $80,987 | $-80,987 |
| OConnell Daniel Joseph | Chief Executive Officer | 0 | $0 | 2 | $107,975 | $-107,975 |
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Insider Activity of Acumen Pharmaceuticals, Inc.
Over the last 12 months, insiders at Acumen Pharmaceuticals, Inc. have bought $0 and sold $258,985 worth of Acumen Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Acumen Pharmaceuticals, Inc. have bought $49.68M and sold $326,498 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,161,290 shares for transaction amount of $40M was made by RA CAPITAL MANAGEMENT, L.P. () on 2023‑07‑21.
List of Insider Buy and Sell Transactions, Acumen Pharmaceuticals, Inc.
| 2025-01-23 | Sale | Zuga Matt | CFO & Chief Business Officer | 28,902 0.0479% | $1.72 | $49,633 | -30.64% | |
| 2025-01-21 | Sale | OConnell Daniel Joseph | Chief Executive Officer | 12,619 0.0202% | $1.59 | $20,102 | -26.38% | |
| 2025-01-21 | Sale | Zuga Matt | CFO & Chief Business Officer | 4,364 0.007% | $1.60 | $6,986 | -26.38% | |
| 2025-01-21 | Sale | Siemers Eric | Chief Medical Officer | 3,219 0.0051% | $1.59 | $5,118 | -26.38% | |
| 2025-01-21 | Sale | Meisner Derek M | Chief Legal Officer & Corp Sec | 3,418 0.0054% | $1.59 | $5,435 | -26.38% | |
| 2025-01-21 | Sale | Barton Russell | Chief Operating Officer | 2,914 0.0047% | $1.61 | $4,692 | -26.38% | |
| 2025-01-03 | Sale | OConnell Daniel Joseph | Chief Executive Officer | 47,778 0.0774% | $1.84 | $87,873 | -34.74% | |
| 2025-01-03 | Sale | Zuga Matt | CFO & Chief Business Officer | 13,235 0.0215% | $1.84 | $24,367 | -34.74% | |
| 2025-01-03 | Sale | Siemers Eric | Chief Medical Officer | 10,859 0.0177% | $1.85 | $20,047 | -34.74% | |
| 2025-01-03 | Sale | Meisner Derek M | Chief Legal Officer & Corp Sec | 11,122 0.0181% | $1.84 | $20,506 | -34.74% | |
| 2025-01-03 | Sale | Barton Russell | Chief Operating Officer | 7,636 0.0125% | $1.86 | $14,225 | -34.74% | |
| 2024-01-19 | Sale | OConnell Daniel Joseph | President and CEO | 15,200 0.0253% | $3.47 | $52,753 | -21.82% | |
| 2024-01-19 | Sale | Meisner Derek M | Chief Legal Officer & Corp Sec | 8,933 0.0149% | $3.48 | $31,048 | -21.82% | |
| 2024-01-18 | Sale | Zuga Matt | CFO & Chief Business Officer | 4,242 0.0075% | $3.71 | $15,717 | -23.10% | |
| 2024-01-18 | Sale | Siemers Eric | Chief Medical Officer | 3,124 0.0055% | $3.71 | $11,604 | -23.10% | |
| 2024-01-18 | Sale | Barton Russell | Chief Operating Officer | 2,833 0.005% | $3.73 | $10,555 | -23.10% | |
| 2023-08-17 | Sale | Ives Jeffrey L. | director | 41,949 0.0739% | $6.49 | $272,334 | -47.66% | |
| 2023-07-21 | RA CAPITAL MANAGEMENT, L.P. | 5.16M 13.1759% | $7.75 | $40M | -52.50% | |||
| 2021-07-06 | RA CAPITAL MANAGEMENT, L.P. | 1.88M 3.8811% | $16.00 | $30M | -67.95% | |||
| 2021-07-06 | Hardie Robert D. | 10 percent owner | 1.06M 2.1993% | $16.00 | $17M | -67.95% |
Total: 24
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| OConnell Daniel Joseph | Chief Executive Officer | 667488 1.1019% | $714,212.16 | 0 | 3 | |
| Zuga Matt | CFO & Chief Business Officer | 231744 0.3826% | $247,966.08 | 0 | 4 | |
| Siemers Eric | Chief Medical Officer | 170298 0.2811% | $182,218.86 | 0 | 3 | |
| Meisner Derek M | Chief Legal Officer & Corp Sec | 161127 0.266% | $172,405.89 | 0 | 3 | |
| Barton Russell | Chief Operating Officer | 136117 0.2247% | $145,645.19 | 0 | 3 | |
| RA CAPITAL MANAGEMENT, L.P. | 13043179 21.5328% | $13.96M | 2 | 0 | <0.0001% | |
| Hardie Robert D. | 10 percent owner | 3951156 6.5229% | $4.23M | 1 | 0 | <0.0001% |
| Sands Capital Ventures Discovery Fund III, L.P. | 10 percent owner | 3417075 5.6412% | $3.66M | 1 | 0 | <0.0001% |
| Manning Paul B | 10 percent owner | 3352693 5.5349% | $3.59M | 1 | 0 | <0.0001% |
| Stalfort John A III | director | 172324 0.2845% | $184,386.68 | 1 | 0 | <0.0001% |
| Fountain Nathan B | director | 6250 0.0103% | $6,687.50 | 1 | 0 | <0.0001% |
| Ives Jeffrey L. | director | 0 0% | $0 | 0 | 1 |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$81,638,324 | 48 | 7.58% | $61.26M | |
$332,528,129 | 45 | 28.82% | $70.94M | |
$22,288,598 | 37 | 25.99% | $67.92M | |
$26,678,853 | 21 | -5.95% | $70.17M | |
$26,736,140 | 20 | -18.64% | $64.91M | |
$1,602,584 | 20 | 15.26% | $64.74M | |
$245,302 | 15 | -4.08% | $63.85M | |
$73,968,137 | 12 | -34.52% | $64.56M | |
$13,919,584 | 9 | -30.43% | $65.23M | |
$32,684,649 | 8 | -15.84% | $64.28M | |
$4,895,542 | 8 | -11.85% | $63.56M | |
Acumen Pharmaceuticals, Inc. (ABOS) | $99,355,998 | 7 | -65.74% | $64.81M |
$195,184 | 5 | 6.34% | $59.41M | |
$6,049,986 | 4 | -8.38% | $60.79M | |
$18,186,879 | 4 | 49.41% | $71M | |
$4,256,958 | 4 | 22.95% | $70.72M | |
$4,249,999 | 4 | 5.44% | $68.68M | |
$19,175,155 | 2 | 40.00% | $65.14M | |
$4,030 | 1 | 9.14% | $62.69M |
ABOS Institutional Investors: Active Positions
| Increased Positions | 35 | +41.18% | 2M | +3.8% |
| Decreased Positions | 32 | -37.65% | 3M | -6.86% |
| New Positions | 14 | New | 232,646 | New |
| Sold Out Positions | 7 | Sold Out | 148,502 | Sold Out |
| Total Postitions | 88 | +3.53% | 42M | -3.06% |
ABOS Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Ra Capital Management, L.P. | $16,127.00 | 24.48% | 14.93M | 0 | 0% | 2024-12-31 |
| Sands Capital Ventures, Llc | $3,690.00 | 5.6% | 3.42M | 0 | 0% | 2024-12-31 |
| Franklin Resources Inc | $3,536.00 | 5.37% | 3.27M | -275,436 | -7.76% | 2024-12-31 |
| Blackrock, Inc. | $2,518.00 | 3.82% | 2.33M | -40,998 | -1.73% | 2025-03-31 |
| Fmr Llc | $2,186.00 | 3.32% | 2.02M | -4,357 | -0.21% | 2024-12-31 |
| Vanguard Group Inc | $2,096.00 | 3.18% | 1.94M | +6,732 | +0.35% | 2024-12-31 |
| Rock Springs Capital Management Lp | $1,986.00 | 3.02% | 1.84M | -461,143 | -20.05% | 2024-12-31 |
| Knollwood Investment Advisory, Llc | $1,759.00 | 2.67% | 1.63M | 0 | 0% | 2024-12-31 |
| Millennium Management Llc | $1,452.00 | 2.21% | 1.34M | -490,008 | -26.71% | 2024-12-31 |
| Alyeska Investment Group, L.P. | $1,015.00 | 1.54% | 939,603 | 0 | 0% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Price to Earnings
Price/Earnings to Growth
Price to Sales
Price to Book
Price/Free Cash Flow
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.